Reprint

COVID-19: Clinical Advances and Challenges

Edited by
January 2024
408 pages
  • ISBN978-3-0365-9839-0 (Hardback)
  • ISBN978-3-0365-9840-6 (PDF)

This book is a reprint of the Special Issue COVID-19: Clinical Advances and Challenges that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

This SI reprint comprehensively explores the ongoing COVID-19 pandemic, addressing various facets, from treatment protocols to global health implications. This 30-article reprint reflects the breadth and depth of the medical community's response to this unprecedented health crisis. Each article brings a unique perspective, contributing to a multifaceted understanding of the pandemic. Topics range from innovative therapeutics and vaccine development to the impact of COVID-19 on different patient populations and healthcare systems globally. This SI includes research articles, reviews, and communications that highlight the rapid advancements in understanding and managing COVID-19 and the challenges faced by healthcare professionals and researchers. One of the notable features of this SI is its focus on the evolving nature of the disease and responses to it. Articles discuss the efficacy of various treatment methods against emerging virus variants, providing crucial insights for ongoing and future pandemic preparedness. This SI also sheds light on the real-world experiences of healthcare providers, patients, and policymakers, offering a holistic view of the pandemic's impact. It is an essential resource for healthcare professionals, researchers, and policymakers. It underscores the importance of high-quality, rapid research in response to global health emergencies and fosters a collaborative approach to overcoming the challenges posed by COVID-19. These articles contribute to the current understanding of the pandemic and lay a foundation for future research and response strategies in the face of similar global health threats.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
COVID-19; SARS-CoV-2; ciclesonide; inhalation; antiviral agents; remdesivir; COVID-19; pneumonia; non-invasive ventilation; mechanical ventilation; COVID-19; COVID-19 vaccine; ChAdOx1-S; BNT162b2; immunogenicity; COVID-19; anakinra; baricitinib; corticosteroids; mortality; anakinra; COVID-19; COVID-19 therapeutics; immunomodulatory treatment; meta-analysis; mortality; updated; COVID-19; bamlanivimab; etesevimab; hospital admission; COVID-19; thromboembolism; tocilizumab; anakinra; hydroxycholoroquine; immunomodulation; anticoagulation; COVID-19; COVID-19 therapeutics; dose; meta-analysis; mortality; thromboprophylaxis; treatment; SARS-CoV-2; BNT162b2; COVID-19; lung ultrasound; COVID-19 pneumonia; imaging; radiology; computed tomography; remdesivir; COVID-19; safety; adverse events; acute kidney injury; nephrotoxicity; COVID-19; SARS-CoV-2; antibiotics; antibacterial agents; mixed methods; qualitative; quantitative; mucormycosis; COVID-19; fungal infection; risk factors; diagnosis; treatment; COVID-19; therapeutics; omicron; coronavirus disease 2019; monoclonal antibodies; Casirivimab plus imdevimab; Sotrovimab; bebtelovimab; remdesivir; molnupiravir; paxlovid; evusheld; corticosteroids; baricitinib; tocilizumab; Anakinra; anticoagulation; timeline; n/a; SARS-CoV-2; COVID-19; long COVID; SPECT; HR-CT scan; lung function test; anticoagulation; COVID-19; COVID-19 therapeutics; dosage; mortality; thromboprophylaxis; treatment; biomarker; COVID-19; Krebs von den Lungen-6; SARS-CoV-2; severity; COVID-19; SARS-CoV-2; children; pandemic; waves; hospitalization; clinical presentation; coronavirus; mucormycosis; steroids; COVID-19; early remdesivir; molnupiravir; ritonavir-boosted nirmatrelvir; sotrovimab; hematological patients; hospitalizations rate; prolonged viral shedding; COVID-19; SARS-CoV-2; bromhexine; standard of care; viral load; primary care; SARS-CoV-2 vaccine; safety; cellular response; CKD; humoral responses; thrombosis; COVID-19; risk prediction model; clinical prediction rule; Coronavirus Disease-2019 (COVID-19); post-acute sequelae of SARS CoV-2 (PASC, long COVID, post-COVID conditions); phenome-wide association study; phenotype risk score; electronic health records; post-acute sequelae; COVID-19; sex hormones; age; antibodies; cellular immunity; COVID-19; humoral immunity; INF-γ release assay; mRNA vaccine; COVID-19; long COVID; machine learning; gradient boosting classifier; long COVID; reinfection; taste dysfunction; smell perception; central nervous system; COVID-19; risk factors; predictors of mortality